HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Shandong Weigao Group Medical Polymer Co (1066.HK) - 2023 Full-Year Results Could Be Ugly

Aier Eye Hospital Group (300015.CH) 23H1 - Time to Face the Gap Between Ideal and Reality

Pre-IPO Xiamen Yan Palace Bioengineering - Concerns About Profitability and Growth Sustainability

Shandong Weigao Group Medical Polymer (1066.HK) - As a Holding Platform, Investment Value Is Limited

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Shandong Weigao Group Medical Polymer Co / Equity Bottom-Up

Shandong Weigao Group Medical Polymer Co (1066 HK)

<ul>
<li>Weigao’s 23H1 performance was unsatisfactory. 2023 full-year performance may continue to be under pressure because Weigao needs some time to digest the negative impact of centralized procurement on orthopaedic business.</li>
<li>Weigao has hired advisers to find potential buyers for Argon. if Argon is ultimately sold, then the long-term prospects of Weigao's interventional business and internationalization need to be reassessed.</li>
<li>The unsatisfactory share price performance is related to Weigao’s business model - spin-off subsidiaries and IPO separately. There could be rebounds, but it is still possible for Weigao to underperform.</li>
</ul>


Weigao’s 23H1 performance was unsatisfactory. 2023 full-year performance may continue to be under pressure because Weigao needs some time to digest the negative impact of centralized procurement on orthopaedic business.
Weigao has hired advisers to find potential buyers for Argon. if Argon is ultimately sold, then the long-term prospects of Weigao's interventional business and internationalization need to be reassessed.
The unsatisfactory share price performance is related to Weigao’s business model - spin-off subsidiaries and IPO separately. There could be rebounds, but it is still possible for Weigao to underperform.


Shenzhen Mindray Bio-Medical Electronics (300760 CH)

Shandong Weigao Group Medical Polymer (1066.HK) - Performance Rebound May Not Be as Fast as Imagined